30 results about "HSF1" patented technology

The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.

The present invention relates to a small molecule polypeptide in HD treatment medicine and application thereof, the amino acid sequence of the small molecule polypeptide is shown in SEQ ID No.1. The invention also provides the application of the small molecule polypeptide. The present invention designs a small molecule polypeptide DH1 through the research on the translocation mechanism and function of HSF1. The polypeptide inhibits the mitochondrial translocation of HSF1, weakens the fragmentation of mitochondria, increases the expression of mitochondrial DNA, and then achieves the purpose of protecting neurons and improving the disease process of HD, and provides a new target for HD treatment.

The invention discloses a heat shock transcription factor 1 dominant negative effect mutant dn-Hsf1 and its application, belonging to the field of biotechnology. Human and A. flavus ( Aspergillus flavus ) in the heat shock transcription factor 1 HSF1 protein, and a total of 213 amino acid residues from the 576th to the 788th position of the C-terminal of the Aspergillus flavus Hsf1 protein were deleted to obtain the heat shock transcription factor 1 dominant negative mutant dn in Aspergillus flavus The amino acid sequence of the -Hsf1 protein is shown in SEQ ID NO.1, and the coding nucleotide sequence is shown in SEQ ID NO.2. The dominant-negative mutant dn-Hsf1 can inhibit the function of normal Hsf1 in fungi, thereby inhibiting the growth of fungi, and is used in the prevention and control of fungal pollution.

The invention discloses sgRNA for up-regulating non-coding RNA expression in a human DLK1-DIO3 imprinted domain, a recombinant plasmid and a cell line. The sgRNA sequence is shown as SEQ ID NO. 1, andspecifically as 5'-TTTATATGGAGGCGCAGAAG-3'; the method comprises the steps of: synthesizing a nucleic acid fragment of a sgRNA sequence and inserting into a multiple cloning site of the MS2-P65-HSF1expression plasmid vector and transforming, and selecting a monoclonal strain, extracting the recombinant plasmid of MS2-P65-HSF1-sgRNA-DLK1-DIO3, and transfecting the recombinant plasmid to the target cell line which is pre-transfected with dCAS9-VP64 plasmid to obtain the cell strain for up-regulating non-coding RNA expression in the DLK1-DIO3 imprinted domain. The application can rapidly, easily and accurately up-regulate the expression of non-coding RNA on the DLK1-DIO3 imprinted domain of the cell strain.

The invention discloses an application of a heat shock transcription factor 1 in regulating expression of a 15kDa selenoprotein. The application provided by the invention is specifically any one of the applications of the heat shock transcription factor 1: (a1) promoting expression of a Sep15 protein in a target cell; (a2) promoting transcription of a Sep15 gene; and (a3) enhancing the activity of a Sep15 promoter in the target cell. According to the application disclosed by the invention, a transcription factor HSF1 can be combined with the Sep15 promoter to adjust transcription of the Sep15 gene and accelerate expression of the Sep15 protein. Under a heat shock and fever of a physiological status, the transcription factor HSF1 can start transcription of Sep15 and improve expression of Sep 15 so as to participate the physiological process and help the protein being corrected folded or help the protein being unfolded and delivered to other proteins to help the proteins to be folded correctly. Under endoplasmic reticulum stress, the HSF1 also can promote expression of Sep 15 to participate protein quality control of endoplasmic reticulum so as to further promote cell survival. The application disclosed by the invention is of important significance in preventing and / or treating endoplasmic reticulum stress related diseases.

The invention provides a method for simultaneously activating multiple porcine endogenous stem cell factors by adopting a tandem sgRNA strategy. Blasticidin and hygromycin drugs are adopted for screening and constructing a PK-15 cell line (PK-15-dCas9-MS2) capable of stably expressing dCAS-VP64 and MS2-P65-HSF1 first, sgRNAs capable of targeting promoters of the porcine stem cell factors Oct4, Sox2, Klf4, c-Myc and miR-302 / 367 are designed and constructed separately, high-activity sgRNA screening is carried out on the cells, the five sgRNAs with the highest gene transcription activation efficiency are serially combined and constructed into an expression vector, and the expression vector is introduced into the PK-15-dCas9-MS2 cells to simultaneously activate the transcriptional activity ofporcine OSKM and miR-302 / 367. The method has a potential application value in induced generation of porcine iPSC.

The present invention relates to compounds of formula I, wherein A 1 、A 2 , R 4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and / or prevention of proliferative diseases such as cancer. The invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising these compounds.

The invention relates to a molecular marker for diagnosing idiopathic inflammatory myopathy and its application. The molecular marker is autologous anti-heat shock transcription factor 1 (heat shock factor 1, HSF1) antibody in serum. The antibody is IgG; the idiopathic inflammatory myopathy is polymyositis (polymyositis, PM) or dermatomyositis (dermatomyositis, DM); the diagnosis is to distinguish idiopathic inflammatory myopathy and healthy population or to predict the disease process of idiopathic inflammatory myopathy (IIM).

The present invention belongs to the biotechnological field and relates to a human myocardial protection gene heat shock transcription factor (HSF1) and a sieving method and a purpose thereof. The present invention adopts the method of ''death trap'' that the gene which resists myocardial cell death is sieved from human cardiac gene, and the human myocardial protection gene heat shock transcription factor 1 is cloned from the obtained gene. The result of transfection cell and animal experiment shows that the obtained human myocardial protection gene has the function of resisting cell death and also has the function of resisting ischemia, protecting myocardial cell and preventing and remedying the heart failure occurrence and development inside the heart of a living organism. The present invention can prepare for the medicine for remedying the ischemic heart disease and preventing the cardiac insufficiency and provides a novel target gene for the further function research and the gene engineering medicine development, which has important meaning for the early prevention and treatment of the heart failure and the research and the development of the related medicines and measures.